Michael H. Tirgan, MD
Founder, Keloid Research Foundation
Medical Oncologist & Global Expert in Keloid Disorder
New York, USA
Dr. Michael H. Tirgan is the Founder of the Keloid Research Foundation and a globally recognized expert in the treatment and research of Keloid Disorder. A board-certified medical oncologist based in New York, Dr. Tirgan has dedicated his clinical practice and academic career to understanding and advancing care for patients suffering from this under-recognized and debilitating condition.
With over two decades of focused experience in keloid management, Dr. Tirgan is the only physician in the United States whose practice is exclusively dedicated to the care of patients with Keloid Disorder. His clinical work includes thousands of patients from across the globe, offering them individualized, evidence-based, and non-surgical treatment strategies.
Dr. Tirgan is a passionate researcher, educator, and advocate for improved care standards in keloid management. He has published extensively on novel treatment approaches, including cryotherapy, intralesional chemotherapy, and topical therapies. Dr. Tirgan is the developer of the Keloid Staging System, a standardized framework designed to classify the severity and extent of Keloid Disorder, and the RECORD (Response Evaluation Criteria in Patients with Keloid Disorder), the first disease-specific tool for assessing treatment outcomes. These pioneering contributions are advancing clinical trials and helping to guide consistent, measurable approaches to care.
In founding the Keloid Research Foundation, Dr. Tirgan created a global platform to foster collaboration among clinicians, scientists, and institutions. Under his leadership, the Foundation has organized multiple international symposia, supported the development of consensus guidelines, and promoted much-needed awareness and research into the complex nature of Keloid Disorder.
Dr. Tirgan’s unwavering commitment to advancing both the science and clinical care of keloids continues to shape the future of this field and improve the lives of patients worldwide.
Let me know i
